Dirk Brockstedt
Director Técnico/Científico/I+D en RAPT THERAPEUTICS, INC. .
Fortuna: 216 996 $ al 30/04/2024
Cargos activos de Dirk Brockstedt
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| RAPT THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/06/2019 | - |
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Consultor / Asesor | - | - |
Historial de carrera de Dirk Brockstedt
Antiguos cargos conocidos de Dirk Brockstedt.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/04/2009 | 01/12/2017 |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Director Técnico/Científico/I+D | 01/01/2007 | 01/01/2009 |
| CERUS CORPORATION | Corporate Officer/Principal | 01/01/2002 | 01/01/2007 |
| Aventis, Inc. | Corporate Officer/Principal | - | - |
Formación de Dirk Brockstedt.
| University of Kiel | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 7 |
| Alemania | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 2 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| CERUS CORPORATION | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 4 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
| Aventis, Inc. | |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
- Bolsa de valores
- Insiders
- Dirk Brockstedt
- Experiencia
